AlphAIAlphAI — Financial news for AI agents
insidermonkey.comSEP 113 min read$DCTH

Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost

Delcath Systems (DCTH) reported Q2 revenue of $29.1M, up from $24.2M YoY, driven by its HEPZATO KIT and CHEMOSAT devices. The company raised its 2026 revenue guidance to $104M-$108M. However, expenses rose, with R&D and SG&A increasing, leading to flat net income. Delcath has $95.9M in cash and no debt, and is expanding into new indications.

Original reporting
insidermonkey.com
Published Sep 11, 2026, 8:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 8:17 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Delcath’s (DCTH) Liver Cancer Device Keeps Growing, But At A Cost — source image
Source · insidermonkey.com
Decision brief

The 30-second read

$DCTHNeutralMed
01

Why it matters

Guidance raise suggests revenue momentum, but rising expenses could limit near‑term profitability.

02

Market read

Earnings and guidance update for a micro‑cap biotech; relevant for niche oncology and small‑cap traders.

03

What to watch

Upcoming Phase 2 trial data could be a larger catalyst than current guidance.

Relevance 7/10Novelty 7/10Timing: Q2 results released Aug 6, guidance fresh for the quarter

Background

Delcath Systems (NASDAQ:DCTH) is a small‑cap interventional oncology company focused on its HEPZATO liver‑directed chemotherapy platform.

Company-level read

Ticker impact

$DCTHNeutralMedium confidence
Context

Delcath Systems reported Q2 results with revenue up to $29.1M and raised full-year guidance to $104M-$108M.

Expected impact

Potential modest price rally on guidance, but volatility from cost concerns.

Evidence & confidence

Guidance increase is a positive catalyst, yet rising R&D and SG&A suggest near‑term earnings pressure.

Market effects

Sector

Positive signal for interventional oncology and liver‑directed therapies.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche oncology investors.

Counterpoint

What could challenge this read

Higher cash burn and flat net income may outweigh guidance upside.

Key entities

  • company
    Delcath Systems

    Interventional oncology firm reporting Q2 results.

Read at source← All news

Related articles

AUG 6
$DCTHMed

DELCATH SYSTEMS, INC. (DCTH): Results of Operations and Financial Condition

DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven

SEC EDGAR 8-K6 min
JUL 9
$DCTHMed

Delcath Systems, Inc.: Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Breast Cancer

Delcath Systems (Nasdaq: DCTH) said the first patient was dosed in its Phase 2 DELUMA trial of HEPZATO plus standard of care versus standard of care alone for liver-dominant HER2-negative metastatic breast cancer. The randomized study will enroll about 90 patients at 20+ sites in the US and Europe, with hepatic progression-free survival as the primary endpoint.

finanznachrichten.de3 min
SEP 11
$SHOEMed

Williams Trading cuts Shoe Station Group stock price target on lower sales outlook

Williams Trading lowered its price target for Shoe Station Group (NASDAQ:SHOE) to $15.00 from a previous target, citing lower sales and earnings estimates. The stock is currently trading at $12.69, down 46% over the past year. The firm expects sequential improvements in sales and margins, with a 5.5% dividend yield and 12 consecutive years of dividend increases. Shoe Station Group reported disappointing Q2 earnings, missing revenue and EPS estimates, with a significant drop in gross profit margi

investing.com2 min
SEP 11
$ORCLHighAI 9/10

Oracle Q1 Results: Cloud Revenue Surges 121% to $7.4bn

Oracle (NYSE: ORCL) reported Q1 2027 revenue of $19.3bn, up 30% YoY, with cloud infrastructure revenue surging 121% to $7.4bn. Non-GAAP operating income rose 31% to $8.2bn, while GAAP EPS increased 55% to $1.56. The company maintained full-year capex guidance of $90bn-$95bn and completed a $20bn stock issuance. Shares were up 8.41% over 20 days, closing at $158.63.

financial-news.co.uk2 min
SEP 11
$KRMedAI 8/10

The Kroger Co. Q2 2026 Earnings Call Summary

Kroger reported Q2 2026 earnings, citing cost savings and e-commerce growth offsetting challenges. Identical sales were impacted by a Cyclospora outbreak and pharmacy headwinds. Full-year guidance lowered to 0.2%–0.8%. Management emphasized strategic shifts in leadership, operational improvements, and a focus on private label brands. Share repurchases totaled $1.2B in H1, with $800M remaining. The company expects inflation pressures in H2 and plans to complete the Giant Eagle acquisition in 2027

yahoo.com3 min